Product Images Gabapentin

This text contains information related to the calculation of creatinine clearance (CLCr) using the equation which involves the patient's weight in grams and serum creatinine in mg/dL. There is a factor of 0.35 for female patients. However, without additional context, it is not possible to determine the purpose or application of this calculation.*

This document appears to be a chart or graph showing pain scores during a clinical trial for a pain medication. The chart shows a 4-week dose titration period followed by a 4-week fixed dose period with either a placebo or gabapentin at 3600 mg/day. There is also a baseline measurement. The only data shown in the document is a mean pain score of 10, with no indication of what scale was used.*

This is a chart showing the results of a study with a 3-week dose titration period followed by a 4-week fixed dose period. The study compares the effects of a placebo with two different doses of gabapentin (1800 mg/day and 2400 mg/day) on mean pain score. There are six time points measured in weeks. No other information is available.*

This is a description of Gabapentin tablets, a medication with the National Drug Code 68382-204-01. The tablets come in 100 count bottles and are distributed by Synergy Pharmaceuticals, a division of Zydus Pharmaceuticals. The tablets contain 600mg of Gabapentin and should be stored at room temperature. The dosage and administration instructions are not clear from the output. Contraindications and side effects are not provided.*

This is the packaging label of a drug called Gabapentin, with the NDC code 68382-205-01. It contains 100 tablets of 800 mg. The manufacturer is Cadis Featherheart L and it is distributed by Zydus Pharmaceuticals in the USA. The label includes information about the usual dosage, prescription details, storage, and precautions.*